EXELIXIS INC
For the period ended Mar 29, 2024. Filed Apr 30, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 29, 2024 · Filed Apr 30, 2024
EXEL$70.58-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (Unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $259,561 | $262,994 |
| Short-term investments | 703,695 | 732,308 |
| Trade receivables, net | 240,577 | 237,407 |
| Inventory | 21,106 | 17,323 |
| Prepaid expenses and other current assets | 67,490 | 67,926 |
| Total current assets | 1,292,429 | 1,317,958 |
| Long-term investments | 629,561 | 728,717 |
| Property and equipment, net | 127,222 | 128,731 |
| Deferred tax assets, net | 361,578 | 361,145 |
| Goodwill | 63,684 | 63,684 |
| Right-of-use assets and other | 329,278 | 342,122 |
| Total assets | $2,803,752 | $2,942,357 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $26,069 | $33,768 |
| Accrued compensation and benefits | 72,958 | 93,325 |
| Accrued clinical trial liabilities | 59,337 | 71,615 |
| Rebates and fees due to customers | 75,651 | 59,619 |
| Accrued collaboration liabilities | 34,704 | 27,533 |
| Other current liabilities | 104,291 | 108,417 |
| Total current liabilities | 373,010 | 394,277 |
| Long-term portion of operating lease liabilities | 201,466 | 189,944 |
| Other long-term liabilities | 101,268 | 94,224 |
| Total liabilities | 675,744 | 678,445 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued | — | — |
| Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 295,032 and 302,793 at March 31, 2024, and December 31, 2023, respectively | 295 | 303 |
| Additional paid-in capital | 2,391,865 | 2,440,710 |
| Accumulated other comprehensive loss | (5,204) | (3,750) |
| Accumulated deficit | (258,948) | (173,351) |
| Total stockholders’ equity | 2,128,008 | 2,263,912 |
| Total liabilities and stockholders' equity | $2,803,752 | $2,942,357 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.